Was Celgene’s Third Quarter Really Crash-Worthy?

Was Celgene’s Third Quarter Really Crash-Worthy?

On the heels of reporting a disappointing late-stage trial failure, Celgene Corp. (NASDAQ: CELG) issued a poor third-quarter financial report that's stoking investors' fears. Has the biotech lost its golden touch, or is it a bargain-bin buy in the making?

Celgene is one of the world's biggest biotech companies. Its track-record includes successfully developing and commercializing four billion-dollar-plus blockbuster drugs: Revlimid, Pomalyst, Otezla, and Abraxane.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com